FDA and MHRA Launch Liaison Program to Tighten Transatlantic Medtech Ties
A new liaison program between the FDA and MHRA is designed to reinforce close collaboration on medical products. For companies trying to commercialize in both markets, the initiative could make regulatory expectations more predictable.
The FDA and MHRA are making a notable bet that closer coordination can improve both oversight and industry efficiency. The new liaison program gives regulators a more formal mechanism to exchange insights, discuss emerging risks, and avoid unnecessary divergence in how products are evaluated.
That is significant because modern medical products increasingly blend hardware, software, and data-driven functionality. When regulatory systems move too far apart, companies spend more time reconciling process differences than improving the actual product. A liaison model will not erase those differences, but it may reduce the number of unnecessary translation layers.
The timing is especially important for digital health and AI-enabled devices, where a product may evolve after launch and where postmarket obligations are just as important as initial approval. Coordinated regulation can help set expectations around monitoring, evidence standards, and lifecycle management in ways that single-agency action cannot fully achieve.
This announcement also suggests that regulators are aware of a competitive reality: if oversight is too fragmented, innovation can migrate to the least burdensome jurisdiction. By building a more coherent transatlantic pathway, the FDA and MHRA are trying to support innovation without surrendering control over safety and quality.